Search…

Hengrui Medicine (01276.HK): SHR-2173 injection approved for clinical trial of drugs.

08/07/2025

The Zhitong Finance and Economics APP news reported that Hengrui Medicine (01276.HK) issued an announcement. Recently, its subsidiary Guangdong Hengrui Medicine Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") for SHR-2173 injection. The company will conduct clinical trials in the near future.

Latest

2 m ago

US stocks surged | Trump Media and Technology Group (DJT.US) rose more than 3%, the company seeks SEC approval for blue-chip cryptocurrency ETF.

3 m ago

Weixing Intelligent (002849.SZ) controlling shareholder Huang Wenqian intends to reduce his shareholding by no more than 1.99%

5 m ago

Xia Fengjian has been appointed as the Deputy Secretary of the Political and Legal Committee of the Shandong Provincial Party Committee and the Secretary of the Party Committee of the Department of Public Security of the province.

6 m ago

The World Gold Council report shows that strong performance in June (+$7.6 billion) drove global gold ETFs to increase by $38 billion in the first half of the year. The total assets under management of these funds surged by 41% to $383 billion, with total holdings increasing by 397 tons to 3,616 tons. North America (+$21 billion) was the main region for fund inflows in the first half of the year, followed by Asia (+$11 billion) and Europe (+$6 billion). The average daily trading volume of gold in the first half of the year was $329 billion, setting a new record for the first half of the year.

6 m ago

World Gold Council: Global gold ETFs increased by $38 billion in the first half of the year, with average daily trading volume reaching a half-year record.

See all latest